Herbs (Global Traditional) · Traditional Chinese Medicine
Ligustrum lucidum
Moderate Evidencebotanical
Hermetica Superfood Encyclopedia
Ligustrum lucidum (Glossy Privet) is a Traditional Chinese Medicine herb containing oleanolic acid and ligustroside as primary bioactive compounds. These compounds work through anti-inflammatory pathways and may support joint health while showing preliminary anti-cancer activity in laboratory studies.
Ligustrum lucidum, known as Nü-zhen-zi or glossy privet fruit, is the mature fruit of a deciduous shrub native to East Asia. The fruit is harvested in autumn, dried, and traditionally processed via wine-steaming or salt-steaming methods to enhance its pharmacodynamics for treating kidney-yin deficiency conditions.
No human clinical trials, RCTs, or meta-analyses have been conducted on Ligustrum lucidum. Current evidence is limited to preclinical animal and in vitro studies, including research on osteoarthritis in rats, glioma xenograft mice models, and hepatocellular carcinoma cell lines (PMID: 25017491).
No clinically studied human dosages exist. Preclinical studies used: methanol extract 50-100 mg/kg (animal studies) or 1-30 mg/mL (in vitro); aqueous extract 100 μg/mL intra-articular or 50-800 μg/mL (in vitro); supercritical CO₂ extract 5-100 mg/L (in vitro). Consult a healthcare provider before starting any new supplement.
Ligustrum lucidum (Chinese Privet/Glossy Privet berry) is not a significant source of macronutrients but is rich in bioactive compounds. Primary actives include oleanolic acid (~0.5–2% dry weight) and ursolic acid (~0.3–1.5% dry weight), both pentacyclic triterpenoids with well-documented biological activity. The fruit contains the iridoid glycoside oleuropein and notably specnuezhenide and nuezhenoside (phenylethanoid glycosides, collectively ~2–5% dry weight), which are considered primary markers of quality. Salidroside (also found in Rhodiola) is present at lower concentrations (~0.1–0.5%). Flavonoids including luteolin, quercetin, and apigenin are present collectively at ~0.5–1.5%. The polysaccharide fraction (Ligustrum lucidum polysaccharides, LLP) comprises approximately 3–8% of dry weight and contributes immunomodulatory effects. Beta-sitosterol and mannitol are also present. Bioavailability of oleanolic acid is notably low orally (~2–3%) due to poor solubility, but is enhanced by lipid co-administration. Phenylethanoid glycosides show moderate gut absorption with partial conversion by intestinal microbiota.
Ligustrum lucidum's oleanolic acid and ligustroside compounds inhibit inflammatory mediators including NF-κB and cyclooxygenase pathways. The herb's triterpene saponins modulate immune responses and may suppress tumor cell proliferation through apoptosis induction and cell cycle arrest mechanisms.
Current evidence for Ligustrum lucidum comes primarily from animal and cell culture studies rather than human clinical trials. Animal studies suggest potential benefits for osteoarthritis pain reduction and cartilage protection, while laboratory studies show anti-cancer activity against glioma and liver cancer cell lines. The preliminary nature of this research means human efficacy and optimal dosing remain unestablished. More robust clinical trials are needed to validate therapeutic applications.
Ligustrum lucidum is generally considered safe when used appropriately in traditional preparations, but comprehensive safety data is limited. Potential side effects may include gastrointestinal upset and allergic reactions in sensitive individuals. The herb may interact with immunosuppressive medications due to its immune-modulating properties. Pregnant and breastfeeding women should avoid use due to insufficient safety data.
